Ectopic pregnancy medical therapy

Ectopic pregnancy Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating an Ectopic Pregnancy from other Conditions

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ectopic pregnancy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ectopic pregnancy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ectopic pregnancy medical therapy

CDC on Ectopic pregnancy medical therapy

Ectopic pregnancy medical therapy in the news

Blogs on Ectopic pregnancy medical therapy

Directions to Hospitals Treating Ectopic pregnancy

Risk calculators and risk factors for Ectopic pregnancy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Overview

[edit | edit source]

There has only been one randomized controlled trail comparing medical to surgical therapy, and there was no difference as far as elimination of the EP or tubal preservation, however the methotrexate (MTX) group had a higher incidence of side effects.

## Medical Therapy

[edit | edit source]

Early treatment of an ectopic pregnancy with the antimetabolite methotrexate has proven to be a viable alternative to surgical treatment[1] since 1933.[2] If administered early in the pregnancy, methotrexate can disrupt the growth of the developing embryo causing the cessation of pregnancy. As actively proliferating trophoblasts have a high rate of de-novo purine and pyrimidine synthesis, they are especially vulnerable to MTX. MTX therapy is generally reserved for EPs < 4 cm on ultrasound in stable patients.

* Dosing regimens include:

* Variable dose: MTX 1 mg/kg IM qod, alternating with leucovorin 0.1 mg/kg IM qod. This is continued until the beta-HCG falls ≥ 15% in 48 hours, or 4 doses of MTX have been given.
* Single dose: MTX 50 mg/m2 IM (can be repeated if beta-HCG on day 7 is ≥ level on day 4). Although more convenient, it has a slightly higher risk of persistent EP.
* Direct injection at the site of implantation has a lower success rate, still requires laparoscopy or ultrasound guidance, and has no benefits consistent with systemic MTX.
* Transient pelvic pain is relatively common with MTX therapy, and it is often difficult to distinguish therapeutic pain from that of a rupturing ectopic.
* Expectant management with watchful waiting works in ~ 68% of patients.

## References

[edit | edit source]

1. ↑ Mahboob U, Mazhar SB (2006). "Management of ectopic pregnancy: a two-year study". Journal of Ayub Medical College, Abbottabad : JAMC. 18 (4): 34–7. PMID 17591007.
2. ↑ Clark L, Raymond S, Stanger J, Jackel G (1989). "Treatment of ectopic pregnancy with intraamniotic methotrexate--a case report". The Australian & New Zealand journal of obstetrics & gynaecology. 29 (1): 84–5. PMID 2562613.CS1 maint: Multiple names: authors list (link)

Template:WH Template:WS